Search Result

Results for "

anti-HCV

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Antibiotic (2) Apolipoprotein (2) Apoptosis (1) Atg8/LC3 (1) Autophagy (1) Bacterial (2) CDK (1) Cyclophilin (6) DNA/RNA Synthesis (6) Fungal (1) HCV (34) HCV Protease (3) HIV (2) Isotope-Labeled Compounds (1) Microtubule/Tubulin (1) Nucleoside Antimetabolite/Analog (3) PAK (1) Parasite (2) PI4K (1) PROTACs (2) Reference Standards (3) SARS-CoV (2) Virus Protease (1)
By Research Areas:	Cancer (4) Infection (34) Inflammation/Immunology (4) Metabolic Disease (2)
Click Chemistry:	Azide (2)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-108764

Mipomersen sodium 2 Publications Verification ISIS 301012	Apolipoprotein HCV	Metabolic Disease
Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has *anti-HCV* effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-17470

Mizoribine 5 Publications Verification NSC 289637; HE 69	HCV SARS-CoV Antibiotic Parasite	Inflammation/Immunology
Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant . Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC₅₀s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively .

HY-N7765

Oenothein B	HCV Bacterial Apoptosis Fungal	Infection Inflammation/Immunology Cancer
Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase .

HY-112712

Cyclophilin inhibitor 1	Cyclophilin HCV	Infection
Cyclophilin inhibitor 1 is a potent and orally bioavailable cyclophilin A inhibitor, with a K_d of 5 nM, shows effective anti-HCV activity, with an EC₅₀ of 98 nM for HCV 2a .

HY-148647

Mipomersen 2 Publications Verification ISIS 301012 free base	Apolipoprotein HCV	Infection
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has *anti-HCV* effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-173011

RJS308	PROTACs Cyclophilin HIV HCV	Infection
RJS308 is a selective Cyclophilin A (CypA) PROTAC degrader. RJS308 induces ubiquitin-dependent CypA degradation by recruiting the VHL E3 ligase complex, and forms a ternary complex with CypA and VHL/elongin C/elongin B. RJS308 exhibits anti-HIV-1 and anti-HCV activities. RJS308 can be used in studies related to viral infections .

HY-141882

DC-LC3in-D5 1 Publications Verification	Atg8/LC3 Autophagy	Infection Inflammation/Immunology Cancer
DC-LC3in-D5 acts as an autophagy inhibitor by attenuating LC3B lipidation. DC-LC3in-D5 binds with LC3B. DC-LC3in-D5 disrupts the LC3B-LBP2 interaction with an IC₅₀ of 200 nM. DC-LC3in-D5 may contribute to anti-HCV or combination researchs in cancer through inhibiting autophagy .

HY-10443

Balapiravir 4 Publications Verification Ro 4588161; R1626	HCV DNA/RNA Synthesis	Infection
Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-N0588

Deapioplatycodin D 3 Publications Verification	HCV	Infection
Deapioplatycodin D is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .

HY-173011A

RJS308 TFA	PROTACs Cyclophilin HIV HCV	Infection
RJS308 TFA is a selective Cyclophilin A (CypA) PROTAC degrader. RJS308 TFA induces ubiquitin-dependent CypA degradation by recruiting the VHL E3 ligase complex, and forms a ternary complex with CypA and VHL/elongin C/elongin B. RJS308 TFA exhibits anti-HIV-1 and anti-HCV activities. RJS308 TFA can be used in studies related to viral infections .

HY-115988

IMB-26	HCV	Infection
IMB-26 is a HCV inhibitor with an EC₅₀ of 2.1 μM. IMB-26 shows potent an anti-HCV activity .

HY-108060A

Valopicitabine dihydrochloride NM283 dihydrochloride	HCV HCV Protease Nucleoside Antimetabolite/Analog	Infection
Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination .

HY-W555382

Pseudane IX 2-Nonylquinolin-4(1H)-one	HCV	Infection
Pseudane IX, a compound isolated from the leaves of Ruta angustifolia, has strong anti-HCV activity with an IC₅₀ value of 1.4 μg/mL. Pseudane IX reduces HCV RNA replication and viral protein synthesis levels .

HY-17470R

Mizoribine (Standard) NSC 289637 (Standard); HE 69 (Standard)	Reference Standards HCV SARS-CoV Antibiotic Parasite	Inflammation/Immunology
Mizoribine (Standard) is the analytical standard of Mizoribine. This product is intended for research and analytical applications. Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant . Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC₅₀s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively .

HY-N3918

γ-Fagarine	HCV	Infection
γ-Fagarine is a furoquinoline alkaloid naturally occurring in Rutae Herba. γ-Fagarine has strong anti-HCV activities with IC₅₀ of 20.4 μg/mL and is also a sister chromatid exchanges (SCEs) inducer .

HY-146648

Cyclophilin inhibitor 3	Cyclophilin HCV	Infection
Cyclophilin inhibitor 3 (compound 7c) is a potent cyclophilin A (CypA) inhibitor with an potent anti-HCV activity (EC₅₀ of 4.2 μM) .

HY-128924

NIM258	Cyclophilin HCV	Infection
NIM258 is a potent nonimmunosuppressive cyclophilin inhibitor (cyclophilin A K_d = 1.2 nM) with *anti-HCV* activity (EC₅₀ = 40 nM). NIM258 can be used for HCV infection research .

HY-108060

Valopicitabine NM283	HCV HCV Protease Nucleoside Antimetabolite/Analog	Infection
Valopicitabine (NM283) is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination .

HY-172230

Anti-infective agent 10	Virus Protease HCV	Infection
Anti-infective agent 10 (Compound Example 30) is a ns5b polymerase inhibitor that can be used as an anti-HCV agent .

HY-16750

Radalbuvir GS-9669	DNA/RNA Synthesis HCV	Infection
Radalbuvir (GS-9669) is a non-nucleoside inhibitor of nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp). Radalbuvir shows strong anti-HCV potency (GT1a intrinsic EC₅₀ = 2.9 nM, GT1b EC₅₀ = 6 nM) .

HY-125182

SMCypI C31	Cyclophilin HCV	Infection
SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC₅₀ of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC₅₀s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction .

HY-157291

Antiviral agent 44	HCV	Infection
Antiviral agent 44 (compound 7b) is an antiviral agent that has *anti-HCV* activity in vitro .

HY-129057

2',5-Difluoro-2'-deoxycytidine	HCV	Infection
2',5-Difluoro-2'-deoxycytidine, compound 13, has potent anti-HCV activity and toxicity to ribosomal RNA (rRNA) .

HY-N8520

Variculanol	Bacterial	Infection Cancer
Variculanol is an antimicrobial, anticancer and anti-HCV NS3/4A Protease agent which can be extracted from marine fungus Aspergillus versicolor .

HY-169746

Antiviral agent 63	DNA/RNA Synthesis HCV	Infection
Antiviral agent 63 is a nucleoside analog with anti-HCV activity. Antiviral agent 63 can inhibit viral replication by inhibiting the activity of HCV RNA-dependent RNA polymerase or other virus-related enzymes .

HY-115989

HCV-IN-38	HCV	Infection
HCV-IN-38 is a potent, selective and orally active HCV inhibitor (EC₅₀=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile .

HY-12730

RG7109	HCV DNA/RNA Synthesis	Infection
RG7109 is an inhibitor of HCV NS5B polymerase. RG7109 has EC₅₀ values of 1.1 nM and 1.0 nM for HCV GT-1a H77 and GT-1b Con1, respectively. RG7109 exhibits favorable pharmacokinetic properties and can be used in anti-HCV research .

HY-W555382S

Pseudane IX-d4 2-Nonylquinolin-4(1H)-one-d₄	Isotope-Labeled Compounds HCV	Infection
Pseudane IX-d₄ (2-Nonylquinolin-4(1H)-one-d₄) is deuterium labeled Pseudane IX. Pseudane IX, a compound isolated from the leaves of Ruta angustifolia, has strong anti-HCV activity with an IC₅₀ value of 1.4 μg/mL. Pseudane IX reduces HCV RNA replication and viral protein synthesis levels .

HY-177299

HCV NS5B polymerase-IN-3	HCV	Infection
HCV NS5B polymerase-IN-3 (Compound 30a) is an inhibitor of the HCV NS5B polymerase. HCV NS5B polymerase-IN-3 exhibits anti-HCV activity in the Huh7 replicon cell line with an EC₅₀ of 0.23 μM and shows no obvious cytotoxicity. HCV NS5B polymerase-IN-3 can be used in research related to the hepatitis C virus .

HY-10443A

Balapiravir hydrochloride Ro 4588161 hydrochloride; R1626 hydrochloride	HCV DNA/RNA Synthesis	Infection
Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity . Balapiravir (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-10443R

Balapiravir (Standard) Ro 4588161 (Standard); R1626 (Standard)	Reference Standards HCV DNA/RNA Synthesis	Infection
Balapiravir (Standard) is the analytical standard of Balapiravir. This product is intended for research and analytical applications. Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-121989

cis-Trismethoxy resveratrol (Z)-3,5,4'-Trimethoxystilbene	Microtubule/Tubulin HCV CDK Akt PAK	Infection Metabolic Disease Cancer
cis-Trismethoxy resveratrol ((Z)-3,5,4'-Trimethoxystilbene) is an anti-HCV agent and Tubulin inhibitor, with an IC₅₀ of 4 μM against Tubulin. cis-Trismethoxy resveratrol induces G2/M phase cell cycle arrest, reduces DCLK1, decreases CDK1 levels, blocks phosphorylation of Akt Ser ⁴⁷³, and induces the expression of p21 ^Cip1/Waf1. cis-Trismethoxy resveratrol exhibits anti-tumor and hepatoprotective activities. cis-Trismethoxy resveratrol can be used in studies related to colon adenocarcinoma, hepatocellular carcinoma, hepatitis C, and liver injury .

HY-107143

BL-8030	HCV	Infection
BL-8030 is an anti-HCV agent. BL-8030 can be used for the research of infection .

HY-186153

Antiviral agent 82	HCV	Infection
Antiviral agent 82 (example 1) is an anti-HCV agent. Antiviral agent 82 can be used to prevent infection with flaviviruses, particularly hepatitis C virus .

HY-108060AR

Valopicitabine dihydrochloride (Standard) NM283 dihydrochloride (Standard)	Reference Standards HCV HCV Protease Nucleoside Antimetabolite/Analog	Infection
Valopicitabine dihydrochloride (Standard) is the analytical standard of Valopicitabine (dihydrochloride) (HY-108060A). This product is intended for research and analytical applications. Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination .

HY-123536

AZD2836 A-831	PI4K HCV	Infection
AZD2836 (A-831) is a 4-aminopyrazolone compound with anti-HCV activity. AZD2836 inhibits the activity of the host cell kinase PI4KIIIα, causing metabolic disorder of the cell membrane component PI4P that is necessary for viral replication. In the HCV subgenomic replicon cell model, the EC₅₀ values of AZD2836 for genotype 1b (Con1 strain) and genotype 1a (Lemon strain) are 270 nM and 550 nM, respectively .

HY-N17997

Pilosulyne D	Others	Infection
Pilosulyne D is a polyyne found in the roots of Codonopsis pilosula .

Cat. No.	상품명

HY-L073

Anti-Hepatitis C Virus Compound Library	391 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

391 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	상품명	Category	Target	Chemical Structure